Co-Founder & CEO Andreas Katopodis describes the company’s three primary programs: a non-specific fusion protein that blocks the alpha receptor of IL-2 to signal CD8 cells but not T-regs, and two bispecifics that use a non-binding PD-1 as a delivery device to home on to the cancer cells.
Also look for unique social pages for BiotechTV U.
Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.
Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.
.png){kind=logo}
